Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9121846 | 0.98 | KDM4E (0.61) | KDM4EHPGDALDH1A1L3MBTL1POLB | |
| SCHEMBL24158897 | 0.85 | KDM4E (0.57) | KDM4EHPGDALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL14352777 | 0.85 | KDM4E (0.57) | KDM4EHPGDALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL14974510 | 0.84 | KDM4E (0.59) | KDM4EHPGDALDH1A1PTGS1PTGS2 | |
| SCHEMBL10513729 | 0.83 | KDM4E (0.55) | KDM4EHPGDALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL27904247 | 0.81 | KDM4E (0.58) | KDM4EHPGDALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL21576143 | 0.81 | KDM4E (0.53) | KDM4EHPGDALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL22581417 | 0.81 | KDM4E (0.76) | KDM4EHPGDALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL15558115 | 0.80 | KDM4E (0.61) | KDM4EHPGDALDH1A1TDP1PTGS1 | |
| SCHEMBL1668064 | 0.79 | ALDH1A1 (0.60) | KDM4EHPGDALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483283-B1 | Method for the manufacture of aminohydroxy diphosphonic acids | STRAITMARK HOLDING AG (CH) | 2015-01-07 | — | — | EP | claimed |
| US-8779135-B2 | Method for the manufacture of aminohydroxy diphosphonic acids | STRAITMARK HOLDING AG (CH) | 2014-07-15 | — | — | US | claimed |
| US-20120245354-A1 | METHOD FOR THE MANUFACTURE OF AMINOHYDROXY DIPHOSPHONIC ACIDS | STRAITMARK HOLDING AG (CH) | 2012-09-27 | — | — | US | claimed |
| US-8003820-B2 | Process for preparing bisphosphonic acids | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-23 | — | — | US | claimed |
| EP-1656386-B1 | A PROCESS FOR PREPARATION OF BISPHOSPHONIC ACID COMPOUNDS | SUN PHARMACEUTICALS IND LTD (IN) | 2009-12-09 | — | — | EP | claimed |
| US-7528280-B2 | Reacting phosphorus acid, 3-pyridylacetic acid in phenol in presence of phosphorus trichloride to produce1-hydroxy-2-(3-pyridinyl)ethylidene-1,1-bisphosphonic acid (Risedronic acid); simple, effective, high purity on a commercial scale | AUROBINDO PHARMA LTD. (IN) | 2009-05-05 | — | — | US | claimed |
| US-7411087-B2 | Process for preparation of bisphosphonic acid compounds | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-12 | — | — | US | claimed |
| WO-2007083240-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF BISPHOSPHONIC ACIDS | AUROBINDO PHARMA LIMITED (IN) | 2007-07-26 | — | — | WO | claimed |
| US-20070173645-A1 | Process for the preparation of biphosphonic acids | AUROBINDO PHARMA LTD (IN) | 2007-07-26 | — | — | US | claimed |
| US-20070142636-A1 | PROCESS FOR PREPARING BISPHOSPHONIC ACIDS | DR. REDDY'S LABORATORIES, INC. | 2007-06-21 | — | — | US | claimed |
| US-20060293524-A1 | Namely alendronic acid, pamidronic acid, risedronic acid, zoledronic acid, ibandronic acid, minodronic acid, neridronic acid and olpadronic acid, by reacting the analogous carboxylic acid with phosphorus trichloride, pentachloride, or oxychloride in sulfolane; industrial scale | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-12-28 | — | — | US | claimed |
| EP-1656386-A2 | A PROCESS FOR PREPARATION OF BISPHOSPHONIC ACID COMPOUNDS | Sun Pharmaceuticals Industries Ltd. (IN) | 2006-05-17 | — | — | EP | claimed |
| WO-2005044831-A2 | A PROCESS FOR PREPARATION OF BISPHOSPHONIC ACID COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20040043967-A1 | Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICALS USA, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | disclosed |
| US-5057526-A | Immunological disorders, suppress organ rejection | BOEHRINGER MANNHEIM GMBH (DE) | 1991-10-15 | — | — | US | disclosed |
| US-4990503-A | A bone resorption inhibitor | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173645-A1 | Process for the preparation of biphosphonic acids | BPGM, PPIP5K2, GNPAT | KDM4E 2517/4885HPGD 1749/4885ALDH1A1 2976/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885HPGD 2028/4885ALDH1A1 1991/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KDM4E 2079/4885HPGD 2028/4885ALDH1A1 1991/4885 |
| US-20070142636-A1 | PROCESS FOR PREPARING BISPHOSPHONIC ACIDS | BPGM, PHOSPHO1, PFKFB2 | KDM4E 4420/4885HPGD 1417/4885ALDH1A1 3201/4885 |
| US-20060293524-A1 | Namely alendronic acid, pamidronic acid, risedronic acid, zoledronic acid, ibandronic acid, minodronic acid, neridronic acid and olpadronic acid, by reacting the analogous carboxylic acid with phosphorus trichloride, pentachloride, or oxychloride in sulfolane; industrial scale | PPARD, P2RY11, SOST | KDM4E 4802/4885HPGD 189/4885ALDH1A1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.